Insights in Biomedicine Open Access

The Future of Polyclonal Antibodies: Emerging Technologies and Trends

Utkarsha Deshpande^* Department of Pharmacy, Sinhgad Institute of Pharmacy, Narhe, Pune, India
^*Correspondence: Utkarsha Deshpande, Department of Pharmacy, Sinhgad Institute of Pharmacy, Narhe, Pune, India, Email:

Received: 17-May-2024, Manuscript No. IPIB-24-19973; Editor assigned: 19-May-2024, Pre QC No. IPIB-24-19973 (PQ); Reviewed: 03-Jun-2024, QC No. IPIB-24-19973; Revised: 13-Mar-2025, Manuscript No. IPIB-24-19973 (R); Published: 20-Mar-2025, DOI: 10.21767/2572-5610.10.1.36

Introduction

Polyclonal antibodies are one of the most useful tools for research and testing in medical fields. Poly means multiple and the term polyclonal refers to the use of antibodies produced from multiple B cell clones. Broadly, this diverse array of antibodies can react with multiple antigens. Polyclonal antibodies have been used in applications such as immunohistochemistry, flow cytometry and enzyme-linked immuno-absorbance assays or ELISA for decades [1].

Description

Emerging Technologies and Trends in Polyclonal Antibodies

Recombinant DNA technology: Recombinant DNA technology is a method used for the creation of novel combinations of genetic material by manipulating DNA molecules. When focusing on polyclonal antibodies, this technology is used to generate antibodies featuring target binding characteristics that are specific to desired targets. For example, recombinant DNA technology assists in the development of antibodies against proteins, peptides and small molecules [2].

Phage display: By using a library of antibody fragments displayed on the surface of a bacteriophage, namely a phage display, the desired antibodies with exceptional binding characteristics may be selected. This technology enables the rapid screening and isolation of high-affinity antibodies against specific targets. Phage display offers advantages such as high throughput, diversity and the ability to engineer antibodies with improved properties.

Monoclonal antibodies: In recent years, monoclonal antibodies have gained popularity because of their specificity and possibility to target a particular antigen. They are generated by similar immune cells that are offspring of a parent cell and as follow are distinct and highly-specific antibodies that are applicable in tailored therapies and diagnostics. For example, “A newly approved monoclonal antibody” Nirsevimab, “designed by pharmaceutical companies Sanofi and AstraZeneca…” got Fast Track FDA a designation that is a procedure to promote access to medicines that treat serious diseases and infections, including those caused by viruses, offering stringent security against RSV [3].

Novel purification techniques: Various purification techniques have been advanced and novel methods for isolating and purifying polyclonal antibodies have been introduced. These methods raised the purity and the yield of the polyclonal antibodies, which made them more optimal as a research or a therapeutic tool. Examples of novel purification techniques include affinity chromatography, protein A/G purification and protein L purification.

Market Overview, Trends and Emerging Markets

The polyclonal antibodies market is experiencing significant growth, driven by factors such as increasing prevalence of chronic diseases, rising demand for personalized medicine and advancements in biotechnology. Polyclonal antibodies market size is expected to cross USD 20 billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036; according to a new research report by research nester. The industry size of polyclonal antibodies was over USD 10 billion in 2023 [4].

The polyclonal antibodies are widely used in oncology, especially cancer diagnosis and targeted therapy. The rise in cancer prevalence and specificity in therapy are expected to drive market growth. Furthermore, polyclonal antibodies industry is extent in terms of research collaboration and funding. In October2022, SAB bio-therapeutics has agreed to terms of an exclusive manufacturing services agreement with Emergent BioSolutions Inc. Under the terms of the agreement, emergent will provide contract development and manufacturing services for SAB’s fully human polyclonal antibody production/products. This collaboration will allow SAB to focus on the research and development of its polyclonal antibodies.

Market is segmented by type into animal source, human source. The human source is expected to take 60% of market share by 2036. The uptake of human sources for the generation of polyclonal antibodies has been increasing owing to their high immunogenicity and specificity. These types of antibodies have an inborn advantage in clinical and therapeutic settings as additional treatment since they have a reduced likelihood of eliciting an immune response following administration in human beings. This feature is especially important in therapeutic modalities and assures their safety and little accidental effects [5].

The Asia Pacific polyclonal antibodies market is expected to contribute up to 38% revenue share in 2036. There are several reasons for its growth. One of the main reasons is a high prevalence of chronic diseases, such as cancer, diabetes and cardiovascular diseases. CVDs second leading cause of death in the Asia-Pacific region. Cancer is the second most common cause of NCD deaths in the Asia-Pacific region after CVDs. Approximately 5 million deaths, or 24% of NCD deaths in 2019, were caused by cancer in Asia-Pacific. Curved demand for the product has been consumed due to the development of various types of diagnostic and therapeutic products such as vaccines, diagnostic kits, among others, wherein polyclonal antibodies play a vital role.

Applications Areas of Polyclonal Antibodies

Diagnostics: Polyclonal antibodies are essential as they are used in diagnostic tests to detect and quantify specific antigens. Techniques, where they are used, include enzymelinked immunosorbent assay method, immunohistochemistry, western blotting, among others, that are used to diagnose the existing diseases and monitor the progress of the patient’s response to treatment.

Therapeutics: Polyclonal antibodies are also used in clinical processes, primarily used in the treatment of different diseases. They help in neutralizing toxins, killing cancerous cells, modulating immune responses, and delivering drugs to the targeted site. They are also essential in immunotherapy as they help identify and destroy pathogens.

Research: Polyclonal antibodies play a crucial role in research studies. They help analyze protein expression and localization, determine whether two proteins interact, and study cell processes. Polyclonal antibodies are an indispensable tool in molecular and cell biology and immunology. With them, scientists can explore how different biological mechanisms work and develop new treatments.

Rising ethical considerations and implications: Polyclonal antibodies have already shown to be a promising tool in both research and commercial applications, offering several advantages over monoclonal antibodies. Nevertheless, their use entails a list of ethical concerns and their implications that should not be disregarded.

Ethical considerations: The first and most important ethical considerations issue is that polyclonal antibodies may be contaminated with other antibodies. In turn, it may introduce numerous unintended consequences, such as false positives or false negatives in diagnostic tests. Secondly, the utilization of polyclonal antibodies in research may also make people question the welfare of animals where the antibodies are retrieved.

Implications: The use of polyclonal antibodies in commercial applications might have profound implications for the healthcare industry. At the same time, while polyclonal antibodies in testing increase the reliability of results, each diagnostic test will become more expensive, in the case of use in drug development, the purer and more potent a drug is obtained for treatment. However, the safety and effect of the drug incorporated with polyclonal antibodies face new risks compared to those formulated without polyclonal antibodies.

Conclusion

Overall, the future of polyclonal antibodies is bright, given the technologies and trends that are likely to reshape the field of study. The use of artificial intelligence and machine learning algorithms will enhance the accuracy and timeliness of antibody production. Additionally, new techniques in antibody engineering and modification will increase the scope of applications for polyclonal antibodies. Ultimately, it is safe to conclude that the future of polyclonal antibodies is promising and filled with opportunities for growth and innovation.

References

1. Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F (2005) Monoclonal versus polyclonal antibodies: Distinguishing characteristics, applications and information resources. ILAR J. 46(3):258-268.

   [Google Scholar] [PubMed]

2. Ascoli CA, Aggeler B (2018) Overlooked benefits of using polyclonal antibodies. Biotechnol Tech. 65(3):127-136.

   [Crossref] [Google Scholar]

3. Stills HF (2012) Polyclonal antibody production. 2012:259-274.

   [Crossref] [Google Scholar]

4. Harjito DA, Alam MM, Dewi RA (2021) Impacts of international sports events on the stock market: Evidence from the announcement of the 18th Asian Games and 30th Southeast Asian Games. Int J Sport Financ. 16(3):139-147.

   [Google Scholar]

5. Wilson R (2008) Innovation in the structuring of Islamic Sukuk securities. Humanomics. 24(3):170-181.

   [Google Scholar]